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Abstract 
Autoregulation of receptor systems by their own ligands is a well established biological phenomenon. While down-regulation of 
the glucocorticoid binding capacity by glucocorticoids has been shown in animals and humans, data on up-regulation processes 
in humans are lacking. To further explore glucocorticoid receptor plasticity in relation to endogenous ligands, glucocorticoid 
binding parameters were assessed in 15 healthy controls before and after oral administration of 1.5 g metyrapone with and without 
dexamethasone pretreatment. Administration of metyrapone resulted in blockade of the feedback of the hypothalamic-pituitary- 
adrenal system as shown by the rise in adrenocorticotropin levels, while pretreatment with 1 mg dexamethasone completely 
suppressed adrenocorticotropin concentrations. Glucocorticoid binding sites per lymphocyte exhibited an increase of 63% following 
metyrapone administration, which was prevented by dexamethasone pretreatment. Comparison of morning and afternoon glucocort- 
icoid binding sites per cell in 11 healthy volunteers further revealed a diurnal rhythm of glucocorticoid receptor sites. These data 
suggest that human lymphocyte glucocorticoid receptors are under autoregulatory control. 
Glucocorticoid receptors (GR) have been identified in numerous 
mammalian and human tissues including brain (1 -3), liver (4), 
lung (51, skin (6, 7 ) ,  and peripheral blood cells (8-10). Although 
several lines of evidence suggest an immunosuppressive effect of 
glucocorticoids with therapeutic implications (1 I), the exact mcch- 
anism of glucocorticoid action in relation to immune function 
remains unsolved. Glucocorticoids have been shown both to 
inhibit lymphocyte proliferation ( 1  1)  and to inducc redistribution 
of circulating lcukocytcs to thc bone marrow ( 1  I ) .  
Exposure to higher doses of glucocorticoids can down-regulate 
the G R  in animals (12) and humans (13, 14). In addition, 
investigations on G R  pharmacology in human leukocytes at 
different times of day (10, 15, 16) or in adrenocortical disorders 
(10, 17, 18) have provided conflicting evidence for a diurnal 
rhythm of G R  (15) and dccrcascd GR numbers in adrenal 
insufficiency (18) or Cushing's syndrome (19), which others were 
unable to confirm (10, 17). 
Down-regulation of G R  by glucocorticoids has been relatively 
easy to study in either experimental animals or  man, while data 
on up-regulation phenomena are available only from animals 
after adrenalectomy (20). Thc present study was designed to 
explore whether an increase in G R  binding capacity can be 
achieved by metyrapone (MET) administration in healthy volun- 
teers mimicking the effect of adrenalectomy and whether this can 
be rcvcrsed by exogenous glucocorticoids. 
Results 
Phurmucologicul churactrristics qf' the G R  
Linear regression analysis was performed on all saturation experi- 
ments; a representative Scatchard plot is shown in Fig. 1 ,  Satura- 
tion experiments clearly revealed only one binding site. The Hill 
coefficient was close to unity ( 1  . O O f O . O O l ) ,  indicating an absence 
of cooperativity of the binding site. 
Specific binding of 6 nM [3H]dexamethasone (['HIDEX) was 
completely displaced by the pure glucocorticoid agonist RU 28362 
with a K i  value of 7.8f2.1 nM, by DEX with a Ki value of 
13.4 & 1.7 nM, and by cortisol with a K,  value of 1 1  7 f 3 1 nM, 
respectively, under equilibrium conditions in three different 
experiments. 
There was a linear relationship between absolute CR and 
lymphocyte number in the assay. 
~ 
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FIG. 1, Scatchard plot of a representative saturation experiment of specific 
[3H]dexamethasone binding to human mononuclear leukocytes. Specific- 
ally bound/free [3H]dexamethasone is plotted versus specifically bound 
[3H]dexamethasone. 
Glucocorticoid binding cupucity in relution to endogenous 
glucocorticoid levels in vivo 
Assessment of diurnal variation of G R  binding pharmacology 
revealed a marked increase of G R  sites per cell in the afternoon 
(2542 f 504 versus 4060 f 1 184 receptor sites per cell; t = 4.33, 
d f =  10, P<O.OOl) contemporaneous with a pronounced fall in 
plasma cortisol (557.3 & 141.5 versus 273.1 & 144.5 nmol/L; t =  
5.55, df=  10, P<O.OOl), while the K, did not change significantly 
(8.6f2.7 versus 10.3k3.3 nM). 
Administration of MET resulted in blockade of l l B -  
hydroxylase activity shown by the rise in adrenocorticotropin 
(ACTH) (Fig. 2; t = 4.5, d f=  14, P < 0.001), which was prevented 
by DEX pretreatment. MET administration also increased the 
G R  sites per cell by 63% within 7 h (Fig. 3; t=3.98, d f =  14, 
P<O.OOl), and this effect was blocked by low dose DEX pretreat- 
ment. Depletion of endogenous glucocorticoids by MET and 
35 
30 
25 
20  
15 
10 
5 
0 
ACTH (pmol/L) 
Baseline MET MET*DEX 
FIG. 2. Mean SE plasma adrenocorticotropin (ACTH) concentrations 
at 1600 h on three consecutive days in 15 healthy controls under baseline, 
metyrapone (MET) and metyrapone plus dexamethasone (MET + DEX) 
pretreated conditions. ACTH levels are significantly increased by MET 
administration (t=4.5, df= 14, P <0.001). This increase is prevented by 
DEX pretreatment. 
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FIG. 3. Mean f SE plasma glucocorticoid receptor (GR) binding sites per 
cell at 1600 h on three consecutive days in 15 healthy controls under 
baseline, metyrapone (MET) and metyrapone plus dexamethasone 
(MET + DEX) pretreated conditions. GR sites per cell are significantly 
increased by MET administration ( t= 3.98, df= 14, P<O.OOI). This 
increase is prevented by DEX pretreatment. 
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FIG. 4. Meanf SE K, values at 1600 h on three consecutive days in 15 
healthy controls under baseline, metyrapone (MET) and metyrapone plus 
dexamethasone (MET + DEX) pretreated conditions. 
subsequent replacement by DEX did not significantly alter the 
K, (Fig. 4). 
No relationship was found between age, sex, body weight, 
ACTH, or  baseline cortisol levels (223.7k75.6 nmol/L) and G R  
binding parameters under the conditions studied. 
Discussion 
Although previous investigations of a possible diurnal rhythm of 
G R  binding parameters have yielded contradictory results (10, 
15, 16), the present study demonstrated clear diurnal rhythm of 
GR sites with no apparent change in GR affinity. Interestingly, 
we did not observe a significant correlation between G R  sites 
and ACTH or cortisol levels, suggesting that plasma concentra- 
tions of endogenous glucocorticoids a t  the time of the G R  assay 
d o  not control the GR sites. Estimation of cortisol profiles several 
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France). Rotiszint 22 was obtained from Roth (Karlsruhe, West Ger- 
many). The incubation buffer consisted of PBS with 5 m M  D-glucose 
added. Stock solutions of unlabelled steroids (50 pM) were prepared in 
incubation buffer containing 5% ethanol. 
Preparation of cells 
A mononuclear cell fraction was prepared by sodium metrizoate-Ficoll 
density gradient centrifugation (26). Cells were washed two times in PBS 
for 10 min, incubated for 60 min at 37 "C, and then washed again to 
allow dissociation of endogenous hormone. Endogenous cortisol levels 
after the washing procedure were below the detection limit of the assay. 
The final concentration of cells was determined using a Coulter Counter 
(Model S5; Coulter Electronics Ltd, England). Viability of cells exceeded 
95%, as judged from their ability to exclude trypan blue. Contamination 
by erythrocytes was less than 10%. contamination by granulocytes and 
monocytes was less than 8 %  and did not differ between the three test 
days. 
Binding assay 
Binding experiments were carried out at 37 'C in plastic microtitre plates 
in a total volume of 0.25 mL. The displacing compound (10 p M  unlabelled 
DEX) was added immediately prior to the addition of [3H]DEX to 
determine nonspecific binding. In saturation studies increasing concentra- 
tions of [3H]DEX from 1 to 40 nM were used. Saturation experiments 
were performed at  equilibrium after 90 min incubation. After incubation 
bound ligand was separated from free ligand by rapid filtration through 
Scatron filters with a Titertek cell harvester by two 5-s washes with assay 
buffer a t  room temperature. The fillers were transferred into plastic vials, 
5 mL of a toluene-based scintillation cocktail was added (Rotiszint 22) 
and they were monitored for tritium in a Beckman LS 1801 counter a t  
about 54% efficiency. All samples were assayed in triplicate with a 
variation within a single experiment of less than 7%. 
Hormone as.say.s 
ACTH was measured by a newly developed immunoradiometric assay 
supplied by the Nichols Institute (San Juan Capistrano, CA,  USA), which 
does not require extraction procedures (27). A soluble sandwich complex 
is formed by a ['251]labelled monoclonal antibody directed against N-ter- 
minal ACTH and a biotin-coupled polyclonal antibody against C-terminal 
ACTH. The sandwich complexes are bound by adding avidin-coated 
plastic beads. Unbound components are washed away and the radioactiv- 
ity bound to the solid phase is monitored in a gamma-counter. The lower 
detection limit was 1.5 pmol/L, and the intra- and interassay coefficients 
of variation were 3% and 6.8%, respectively. 
Cortisol was measured by a direct RIA (28). The lower detection limit 
was 25 nmol/L, and the intra- and interassay coefficients of variation 
were 5 %  and I YO, respectively. As there is cross-reactivity of most cortisol 
antibodies with I I-deoxycortisol (about 15% in our assay), assessments 
of cortisol values following MET application would not be accurate and 
were therefore excluded from further analysis. 
Data analysis 
Preliminary estimates of binding parameters from saturation experiments 
were provided by the EBDA program (29). Final estimates of binding 
parameters were determined with a computerized non-linear, least-square 
regression analysis (30). This weighted curve fitting program assumes 
binding according to the law of mass action to independent classes of 
binding sites. 
The results are expressed as the meankSD,  and as the meankSE in 
Figs. 2 to 4. 
Data were analysed using the I-test for paired samples and Pearson's 
product moment correlation. All significance levels are two-tailed. 
hours prior to  that of G R  sites however might clarify the 
relationship of G R  sites and endogenous glucocorticoids. 
We demonstrated an increase in G R  activity binding 7 h 
following MET pretreatment. At this time ACTH levels had also 
increased dramatically due to the lack of feedback action of 1113- 
hydroxylated endogenous glucocorticoids. This increase could be 
prevented by prior administration of the synthetic glucocorticoid 
DEX. Since glucocorticoids probably need several hours to exert 
a notable influence on G R  regulation, this might explain the lack 
of correlations between G R  sites and plasma cortisol concentra- 
tions at the time of the G R  assay. 
Our results in humans accord with those of animal studies and 
recent in vitro investigations at  the protein and DNA level. A 
rise in G R  sites in the rat brain has been observed following 
adrenalectomy (20), while exposure to glucocorticoids results in 
a down-regulation of G R  sites of various cell lines (13, 14, 21). 
While glucocorticoids reduce G R  mRNA (22, 23) and G R  protein 
(24) within several hours following binding of G R  to G R  cDNA, 
receptor degradation may also be involved as an autoregulatory 
post-translational control mechanism independent of G R  protein 
synthesis (21, 25). 
Although changes in G R  binding do not necessarily reflect 
changes in receptor mass, since the results of binding studies are 
dependent on the availability of receptors for exchange with 
radiolabelled tracer, an exact estimation of G R  sites after sufficient 
dissociation of endogenous glucocorticoids has been claimed (1 3). 
The use of monoclonal antibodies and mRNA probes (24) may 
help to discriminate between transcriptional and post-transla- 
tional phenomena and further our understanding of human 
physiology. 
Materials and Methods 
Subjects 
Fifteen subjects (three men and twelve women) participated in the study 
on a voluntary basis. Their mean age and body weight were 47.3k6.9 
(+SD) years and 68.8 k9.9 kg, respectively. Exclusion criteria included 
illness, intake of medication, alcohol or nicotine abuse and stressful life 
events prior to the investigation. Five women were tested during the 
midluteal phase of the cycle and seven were postmenopausal. Diurnal 
variation of G R  characteristics was assessed in an additional I 1  healthy 
volunteers (six men and five women) with a mean age of 35.2k 15.2 years 
and a mean body weight of 67.2k8.9 kg. 
Test protocol 
All subjects were admitted to a sleep laboratory at  least 1 h prior to drug 
administration or blood sampling. The test protocol was approved by 
the ethical committee of the University of Wiirzburg. For determination 
of G R  binding characteristics and hormone data 50 ml blood samples 
were collected at 1600 h into prechilled plastic tubes containing EDTA 
on three consecutive days. On Day 1 baseline values were obtained. On 
Day 2 the subjects were pretreated with 1.5 g MET at  0900 h administered 
orally with milk to avoid severe gastric symptoms. One mg DEX was 
given orally a t  2300 h. On Day 3 administration of 1.5 g MET was 
performed as described for the day before. Twelve of the 15 subjects 
experienced a transient dizziness and a hot flush, which disappeared 
within 45 to 60 min. 
For the evaluation of diurnal G R  binding parameters blood samples 
were obtained twice a t  0800 h and 1600 h. 
Chemicals 
[3H]DEX ([I ,2,4,6,7-3H]dexamethasone, specific activity 84 Ci/mmol) was 
obtained from Amersham, UK. Unlabelled DEX, cortisol, phosphate- 
buffered saline (PBS) and sodium metrizoate-Ficoll were obtained from 
Sigma (St. Louis, MO, USA), and R U  28362 from Roussel-Uclaf (Paris, 
Accepted 12 June 1990 
References 
I .  Fuxe K ,  Wikstrom AC, Okret S, Agnati LF, HPrfstrand A, Yu Z Y ,  
Granhol L, Zoli M,  Vale W, Gustafsson JA. (1985). Mapping of 
glucocorticoid receptor immunoreactive neuro.is in the rat tel- and  
diencephalon using a monoclonal antibody against the rat  liver gluco- 
corticoid receptor. Endocrinology. 117: 1803-1812. 
806 Glucocorticoid binding capacity in human lymphocytes 
2. McEwen B, Chao H, Spencer R. Brinton R, Macisaac L, Harrelson 
A. (1987). Corticosteroid receptors in brain: relationship of receptors 
to effects in stress and aging. Ann NY Acad Sci. 512: 394-401. 
3. De Kloet ER, Ratka A, Reul JMHM, Sutanto W, van Eekelen JAM. 
(1987). Corticosteroid receptor types in brain: regulation and putative 
function. Ann NY Acad Sci. 512: 351-361 
4. Westphal HM, Moldenhauer G. Beato M. (1982). Monoclonal anti- 
bodies to the rat liver glucocorticoid receptor. EMBO J. 1: 1467-1471. 
5 .  Ballard PL, Ballard RA. (1974). Cytoplasmic receptors for glucocort- 
icoids in lung of the human fetus and neonate. J Clin Invest. 53: 
477-486. 
6. Berkovitz GD,  Carter KM,  Migeon CJ. Brown TR. (1988). Down- 
regulation of the glucocorticoid receptor by dexamethasone in cultured 
human skin fibroblasts: implications for the regulation of aromatase 
activity. 3 Clin Endoerinol Metab. 66: 1029 -1036. 
7. Oikarinen A, Oikarinen H,  Meeker CA, Tan EML. Uitto K. (1987). 
Glucocorticoid receptors in human skin fibroblasts: evidence for down- 
regulation of receptor by glucocorticoid hormone. Acta Derm Venereol 
(Stockh). 67: 461-468. 
8. Lippman M, Barr R. (1977). Glucocorticoid receptors in purified 
subpopulations of human peripheral blood lymphocytes. J Immunol. 
118: 1977-1981. 
9. Martins VR, Birolli MIA, Duarte AJS, Brentani MM. (1987). Gluco- 
corticoid receptors in subpopulations of human lymphocytes defined 
by monoclonal antibodies. Cell Immunol. 105: 443-446. 
10. Junker K .  (1983). Glucocorticoid receptors of human mononuclear 
leukocytes in vitro. J Clin Endocrinol Metah. 57: 506-512. 
1 1 .  Cupps TR,  Fauci AS. (1982). Corticosteroid-mediated immunoregul- 
ation in man. lmmunol Rev. 65: 133- 155. 
12. Reul JMHM, van den Bosch FR, de Kloet ER. (1987). Differential 
response of type I and type 11 corticosteroid receptors to changes in 
plasma steroid level and circadian rhythmicity. Neuroendocrinology. 45: 
407-41 2. 
13. Schlechte JA, Ginsberg BH, Sherman BM. (1982). Regulation of the 
glucocorticoid receptor in human lymphocytes. J Steroid Biochem. 16: 
69-74, 
14. Shipman GF,  Bloomfield CD,  Gajil-Peczalska K, Munck AU, Smith 
KA. (1983). Glucocorticoids and lymphocytes. 111. Effects of glucocort- 
icoid administration on lymphocyte glucocorticoid receptors. Blood. 
15. Schlaghecke R, Kley HK.  (1986). Circadian and seasonal variations 
of glucocorticoid receptors in normal human lymphocytes. Steroids. 
16. Doe RP, Goldman PM, Severson SP, Hruby HM. (1986). Circadian 
variation of cytosol glucocorticoid receptors in human polymorphonu- 
61: 1086-1090. 
47: 287- 294. 
clear leukocytes (PMN) and mononuclear cells (MN) in a normal 
population. J Steroid Biochem. 25: 483-487. 
17. Kontula K, Pelkonen R, Anderson L, Sivula A. (1980). Glucocort- 
icoid receptors in adrenocortical disorders. J Clin Endocrinol Metab. 
51: 654-657. 
18. Schlechte JA. Sherman BM. ( I  982). Decreased glucocorticoid 
receptor binding in  adrenal insufficiency. J Clin Endocrinol Metah. 54: 
145 149. 
19. Davydova IV, Nikolaeva NY, Golilov PP. Kalinin AP. (1987). 
Glucocorticoid receptors of blood lymphocytes in Icenko-Cushing 
disease. Probl Endokrinol (Mosk). 33: 28-31. 
20. Reul JMHM, van den Bosch R,  de Kloet ER.  (1987). Relative 
occupation of type I and type 11 corticosteroid receptor; in rat brain 
following stress and dexamethasone treatment: functional implications. 
J Endocrinol. I 15: 459- 467. 
21. Svec F, Rudis M. (1981). Glucocorticoids regulate the glucocorticoid 
receptor in the AtT-20 cell. J Biol Chem. 256: 5984-5987. 
22. Okret S, Poellinger L, Dong Y, Gustafsson JA. (1986). Down- 
regulation of glucocorticoid receptor mRNA by glucocorticoid hor- 
mones and recognition by the receptor of a specific sequence within a 
receptor cDNA clone. Proc Natl Acad Sci USA. 83: 5899-5903. 
23. Kalinyak JE ,  Grifin CA, Hamilton RW, Bradshaw JG, Perlman AJ, 
Hoffman AR. (1989). Development and hormonal regulation of gluco- 
corticoid receptor messenger RNA in the rat. J CLin Invest. 84: 1843- 
1848. 
24. Dong Y, Poellinger L, Gustafsson JA, Okret S .  (1988). Regulation 
of glucocorticoid receptor expression: evidence for transcriptional and 
posttranslational mechanisms. Mol Endocrinol. 2: I256 - 1264. 
25. Mclntyre WR, Samuels HH. (1985). Triamcinolone acetonide regu- 
lates glucocorticoid-receptor levels by decreasing the half-life of the 
activated nuclear-receptor form. J Biol Chem. 260: 418-427. 
26. Boyum A. (1986). Separation of leukocytes from blood and bone 
marrow. Scand J Clin Lab Invest. 21: 97-107. 
27. Raff H, Findling JW. (1989). A new immunoradiometric assay for 
corticotropin evaluated in normal subjects and in patients with Cush- 
ing's syndrome. Clin Chem. 35: 596-600. 
28. Stalla GK,  Giesemann G, Miiller OA, Wood WG, Scriba PC. (1981). 
The development of a direct homologous radioimmunoassay for serum 
cortisol. J Clin Chem Clin Biochem. 19: 427-434. 
29. McPherson GA. (1983). A practical computer-based approach to the 
analysis of radioligand binding experiments. Comput Methods Programs 
Biomed. 17: 107-114. 
30. Munson PJ, Rodbard D. (1980). LIGAND: a versatile computerized 
approach for characterization of ligand-binding systems. Anal Biochem. 
107: 220-239. 
